{"id":"W2996535743","doi":"10.3233/blc-190252","title":"Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial","year":2019,"lang":"en","type":"article","venue":"Bladder Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Ipsen; Incyte; Astellas Pharma; Clovis Oncology; Exelixis; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Docetaxel; Ramucirumab; Medicine; Internal medicine; Placebo; Hazard ratio; Subgroup analysis; Oncology; Chemotherapy; Adverse effect; Progression-free survival; Urology; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003833496,0.001226247,0.003700209,0.0006902072,0.0003066088,0.001113211,0.0005493598,0.0008658523,0.002670658],"category_scores_gemma":[0.002999924,0.0003900524,0.007612275,0.000614128,0.0004537301,0.0005537096,0.0004379675,0.00142166,0.0003114414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000584109,"about_ca_system_score_gemma":0.0007385996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006298925,"about_ca_topic_score_gemma":0.00271518,"domain_scores_codex":[0.9979331,0.001172993,0.0002937595,0.0002655825,0.0001578602,0.0001767087],"domain_scores_gemma":[0.9988269,0.0004838865,0.0003071071,0.0001778544,0.00006598386,0.0001382584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9238085,0.0009936736,0.01065384,0.00209088,0.03148025,0.0001674695,0.00008852952,0.0007909853,0.00248846,0.0001381913,0.001073041,0.02622629],"study_design_scores_gemma":[0.8047874,0.06967835,0.0454605,0.0004250999,0.07188899,0.000383818,0.0001798593,0.001534974,0.001523824,0.0007964348,0.003263528,0.00007720411],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9592202,0.03464629,0.000671844,0.0004211708,0.0004549504,0.001333039,0.001526922,0.00005195268,0.001673612],"genre_scores_gemma":[0.9930602,0.003598035,0.0003888046,0.0003663324,0.0002517612,0.00075613,0.0009129428,0.00001282018,0.0006530076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003833496,"threshold_uncertainty_score":0.02027375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01650419932740946,"score_gpt":0.2940631657067778,"score_spread":0.2775589663793683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}